In a pregnant patient with iron‑deficiency anemia, how should ferumoxytol (Feraheme) be used, including appropriate dosing, timing, and safety considerations compared with other IV iron formulations?

Feraheme (Ferumoxytol) Use in Pregnant Patients with Iron-Deficiency Anemia

Ferumoxytol can be safely and effectively used in pregnant patients with iron-deficiency anemia after 13 weeks gestation, administered as 1020 mg (two vials) in 100 mL normal saline infused over 30 minutes in a single visit, which provides superior hemoglobin improvement compared to oral iron while avoiding the hypophosphatemia risk associated with ferric carboxymaltose. 1

Dosing and Administration

Recommended Regimen

• Dose: 1020 mg total iron (two 510 mg vials)
• Dilution: Mix in 100 mL normal saline
• Infusion time: 30 minutes
• Number of visits: Single infusion preferred over two separate doses 1

The FDA label specifies 510 mg doses given 3-8 days apart over at least 15 minutes 2, but expert consensus guidelines and clinical evidence support single 1020 mg infusions as equally safe and more convenient 1. Studies demonstrate no increase in adverse events with single-dose administration while significantly reducing patient visits and costs 3, 4, 5.

Infusion Protocol

• Start the infusion slowly and observe for several minutes
• If no reaction occurs, complete the remaining infusion over the balance of 30 minutes 1
• Monitor blood pressure and pulse during and immediately after administration 2
• Do not administer routine 30-minute post-infusion monitoring - this is not indicated per expert consensus 1

Timing in Pregnancy

Avoid IV iron before 13 weeks gestation 1. After the first trimester, ferumoxytol can be administered at any point when iron-deficiency anemia is diagnosed. The evidence shows:

• Hemoglobin improvements occur within 1-2 weeks of treatment 1
• Mean hemoglobin increase of 1.86 g/dL in pregnant patients receiving ferumoxytol versus 0.79 g/dL with oral iron 3
• Ferritin increases by median 64.5 ng/mL versus 8 ng/mL with oral iron 3

Safety Considerations

Advantages Over Other IV Iron Formulations

Ferumoxytol is preferred over ferric carboxymaltose (FCM) in pregnancy because:

• FCM causes treatment-emergent hypophosphatemia in 38.7% of patients versus 0.4% with ferumoxytol 6
• FCM should be avoided in patients requiring repeat infusions due to hypophosphatemia risk 1
• Both formulations show comparable hemoglobin improvements, but ferumoxytol has superior phosphorus safety profile 6

Hypersensitivity Risk Management

The incidence of serious adverse events with properly administered ferumoxytol is "vanishingly rare" with minor infusion reactions occurring in only 1-3% of cases 1. Key safety points:

• Do not use premedication routinely - reserve only for patients at high risk of hypersensitivity reactions 1
• Personnel and therapies for treating anaphylaxis must be immediately available 2
• Hypersensitivity reactions can occur even in patients who tolerated previous doses 2
• Greater risk exists in patients with multiple drug allergies 2

Generic Ferumoxytol Warning

Exercise extreme caution with generic ferumoxytol - the generic formulation showed double the incidence of infusion reactions compared to brand name, with one death reported in FDA filing data 1. Without published safety data, practitioners should mandate brand name Feraheme when prescribing to prevent pharmacist substitution 1.

Comparison with Oral Iron

Ferumoxytol demonstrates clear superiority over oral iron in pregnancy:

• Hemoglobin improvement: 1.86 g/dL vs 0.79 g/dL (p<0.0001) 3
• Tolerability: Significantly fewer drug-related adverse events and less nausea 3, 7
• Convenience: Single visit versus daily dosing throughout pregnancy
• Compliance: No gastrointestinal side effects that limit oral iron adherence 4

Important Caveats

MRI Interference

Ferumoxytol is a superparamagnetic iron oxide that will interfere with MRI interpretation for up to 8 weeks after administration 1. Notify radiologists if MRI is planned within this timeframe.

Laboratory Monitoring

• Do not check iron parameters within 4 weeks of infusion - circulating iron interferes with assays 1
• Recheck CBC and iron studies (ferritin, transferrin saturation) at 4-8 weeks post-infusion 1
• Target ferritin goal: 50 ng/mL regardless of sex 1
• Expected hemoglobin rise: 1-2 g/dL within 4-8 weeks 1

Medication Timing

Allow 30 minutes between ferumoxytol administration and other medications in patients at high risk for hypersensitivity reactions 1.

Clinical Evidence Quality

The recommendation is based on 2024 expert consensus guidelines from the American Journal of Hematology [1-1], FDA labeling 2, and high-quality randomized controlled trials in pregnant populations 3, 7. A 2023 RCT specifically in pregnancy (N=124) demonstrated ferumoxytol's superiority with excellent tolerability 3, while a 2021 prospective study of 131 consecutive pregnant women showed no adverse events with either single or split dosing 4.

1, 2, 3, 4, 6, 5, 7